Adjuvant Therapy in Resectable Gastric Cancer
Author Information
Author(s): H. Bleiberg, B. Gerard, P. Deguirall
Primary Institution: Institut Jules Bordet, Centre des Tumeurs de l'Universite Libre de Bruxelles, Brussels, Belgium
Hypothesis
Can adjuvant treatment improve survival rates in patients with resectable gastric cancer?
Conclusion
The review indicates that while some adjuvant treatments show promise, many trials have not demonstrated significant improvements in survival.
Supporting Evidence
- Adjuvant chemotherapy with Mitomycin C showed a 5-year survival rate of 80% compared to 30% for surgery alone.
- 5FU/MeCCNU treatment resulted in a 5-year survival rate of 44% compared to 31% for surgery alone.
- Cimetidine treatment resulted in a median survival time of 15 months compared to 10 months for surgery alone.
Takeaway
This study looks at different treatments for stomach cancer after surgery and finds that some treatments might help, but many studies didn't show clear benefits.
Methodology
The study reviews 24 randomized clinical trials focusing on adjuvant treatments for gastric cancer published since 1965.
Potential Biases
Imbalances in patient characteristics across treatment groups could lead to erroneous conclusions.
Limitations
Many trials had small sample sizes and did not adequately consider important prognostic factors.
Participant Demographics
The trials included patients with resectable gastric cancer, but specific demographics were not detailed.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website